目的:本研究旨在阐明循环外泌体miRNAsmiRNA21,miRNA184和miRNA145在研究组中的表达,包括患有(i)白斑的患者;(ii)口腔粘膜下纤维化;(iii)口腔粘膜下纤维化伴白斑的患者;(iv)口腔鳞状细胞癌;和(v)健康个体。
方法:在Saveetha牙科学院和医院门诊报告的54名患者中进行了一项观察性研究。患者分为三组:第一组健康个体(n=18),II组:病例组(白斑,OSMF,和白斑和OSMF)(n=18),和组III:OSCC(n=18)。进行实时聚合酶链反应分析以评估miRNA21,miRNA184和miRNA145的表达谱。采用SPSS软件23版进行统计分析。
结果:所有三种miRNA在病例组之间的单向ANOVA检验中显示出统计学上的显着差异(白斑,OSMF,和白斑和OSMF),健康组,和OSCC组(p<0.005)。病例组(白斑,OSMF,与明显健康的个体相比,白斑和OSMF)显示miRNA21和miRNA184的表达上调,变化为三倍和四倍,miRNA145的表达下调,变化为1.5倍。
结论:血浆循环外泌体miRNAmiRNA21,miRNA145和miRNA184的表达可能是一组新的血浆生物标志物,用于分类病例组(白斑,OSMF,白斑和OSMF)患者的恶变风险很高。
OBJECTIVE: This study aims to elucidate the expression of circulating exosomal miRNAs miRNA 21, miRNA 184, and miRNA 145 in the studied groups, including patients with (i) leukoplakia; (ii) oral submucous fibrosis; (iii) oral submucous fibrosis with leukoplakia; (iv) oral squamous cell carcinoma; and (v) healthy individuals.
METHODS: An observational study was conducted among 54 patients who reported to the outpatient department of Saveetha Dental College and Hospitals. The patients were divided into three groups: Group I healthy individuals (n = 18), Group II: case group (leukoplakia,
OSMF, and leukoplakia and
OSMF) (n = 18), and Group III: OSCC (n = 18). Real-time polymerase chain reaction analysis was carried out to assess the expression profiles of miRNA 21, miRNA 184, and miRNA 145. The statistical analysis was calculated using SPSS software version 23.
RESULTS: All three miRNAs showed a statistically significant difference in the one-way ANOVA test between the case group (leukoplakia, OSMF, and leukoplakia and
OSMF), healthy group, and OSCC group (p < 0.005). The case group (leukoplakia,
OSMF, leukoplakia and
OSMF) showed upregulated expression of miRNA 21 and miRNA 184 with threefold change and fourfold change and downregulated expression of miRNA 145 with 1.5-fold change when compared to apparently healthy individuals.
CONCLUSIONS: Plasma circulating exosomal miRNAs miRNA 21, miRNA 145, and miRNA 184 expression could be a novel panel of plasma biomarkers to categorise case group (leukoplakia, OSMF, leukoplakia and
OSMF) patients with a high risk of malignant transformation.